TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03863808

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy
Description: Following assessment a one on one session will be given comprising education cognitively targeting false ideas and beliefs on the nature of pain, differentiating nociception due to a painful stimulus and the transition of such a stimulus to a centrally sensitized experience due to misinformation, maladaptive behaviour and fear avoidance. Upon completion of the session assessment using the NPQ will be done to assess the understanding of the patient and further address any shortcomings in future exercise sessions.~Another SEMG recording of the Flexion Relaxation phenomenon will be upon completion of the educational session and a SEMG biofeedback session will begin to help the patient regain their sense of control over their body and function.~After the SEMG biofeedback session a graded exposure exercise program of strengthening and functional training starting from the least feared movements to the most over 10 sessions over 5 weeks.
Study: NCT03769792

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood and faeces tests
Description: During V0 - Laboratory tests, particularly for calprotectin concentration assessment

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Impedance spectroscopy test
Description: During V1 - the electrical impedance of pelvic floor muscles will be measured

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Full gynecological and proctological examination
Description: During V1 - Examination with a gynecological speculum, Two-handed examination, Rectal examination and Anoscopy
Study: NCT03863808

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strengthening exercises
Description: Strengthening exercises in a gradual manner to the Multifidus and Transversus Abdominis muscles.
Study: NCT00544037

Intervention type: DRUG
Intervention: Interferon beta-1b (Betaseron, BAY86-5046)
Description: Standard Therapy for Multiple Sclerosis
Study: NCT04705506

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemigliptin
Description: We collected baseline data from all participants for demographic characteristics,comorbid conditions and biochemistry indexes.The biomarkers for vascular calcification and renal injury were collected.Baseline CAC score and CAVI were done.The patients then were randomized into 2 groups: Group 1 received gemigliptin 50 mg /day for 6 months in addition to standard treatment ,Group 2 will have standard treatment for diabetes mellitus (DM) and chronic kidney disease (CKD).The patients will be followed up every eight weeks.Fasting plasma glucose ,BUN creatinine and 24 hour urine protein were measured at each study visit.Patients were scheduled for follow-up visits at months 2,4,and 6.After 6 months ,all the blood tests,CAC score and CAVI will be done again.
Study: NCT03769792

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Transanal ultrasonography
Description: During V2 - reference diagnostic methods with documented effectiveness and safety; for comparison with impedance spectroscopy results.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Anorectal manometry
Description: During V2 - reference diagnostic methods with documented effectiveness and safety; for comparison with impedance spectroscopy results.
Study: NCT02185040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-220
Description: 0.3 mg oral capsules once every other day with or without food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-220
Description: Subjects will receive 0.3 mg oral capsules every day with or without food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-220
Description: CC-220 oral capsules 0.6 mg and 0.3 mg on alternating days with or without food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-220
Description: CC-220 oral capsule 0.6 mg QD with or without food

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching oral placebo daily
Study: NCT01163409

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: exercise training
Description: exercise training comprises aerobic and strength training

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: acupuncture involves two sessions per week, during 14 weeks.
Study: NCT00623753

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EnvDNA, PolyEnv1, EnvPro
Description: Description: The vaccine regimen is a series of 6 injections given 28 days apart. EnvDNA is administered intramuscularly as 100 mcg of recombinant DNA in 1.5 mL of PBS as injections #1, 2 and 5. PolyEnv1 is recombinant vaccinia virus administered subcutaneously as 107 pfu in 0.8 mL of PBS as injection #3. EnvPro is administered intramuscularly as 100 mcg of recombinant protein and 500 mcg of aluminum hydroxide (alum) adjuvant in 1.0 mL of PBS as injections #4 and 6.
Study: NCT03734601

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total body irradiation (TBI)
Description: Administer Total body irradiation (TBI) 80 cGy on Day 1 of standard TLI ATG conditioning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-thymocyte globulin (ATG)
Description: Given intravenous (IV), Dose 1.5 mg/kg x 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Oral, Dose 0.05 mg/kg twice daily, can be given intravenous (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Description: Given Oral, 15 mg/k every 2 hours for peripheral blood stem cells (PBSC) from matched related donors; 15 mg/kg every 8 hours for PBSC from unrelated donors (URDs) or mismatched related donors.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total lymphoid irradiation (TLI)
Description: 9 x 120 cGy over 11 days
Study: NCT01163409

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercise, Acupuncture and Fibromyalgia
Description: Set of real acupuncture treatment and supervised aerobic exercise have better efficacy in pediatric patients with fibromyalgia versus treatment with sham acupuncture and supervised aerobic exercise, as well as treatment versus combination with aerobic exercise and resistance exercise the major muscle groups, both supervised versus group control, we just get guidance for physical activity.
Study: NCT00156962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin alfa DT
Description: Receive drug at same frequency and dose as at the time of randomization Change dose by+/- 25% in order to maintain Hb between 11.0 - 13.0 g/dL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin alfa RB
Description: Receive drug at same frequency and dose as at the time of randomization Change dose by+/- 25% in order to maintain Hb between 11.0 - 13.0 g/dL
Study: NCT04705506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemigliptin
Description: We collected baseline data from all participants for demographic characteristics,comorbid conditions and biochemistry indexes.The biomarkers for vascular calcification and renal injury were collected.Baseline CAC score and CAVI were done.The patients then were randomized into 2 groups: Group 1 received gemigliptin 50 mg /day for 6 months in addition to standard treatment ,Group 2 will have standard treatment for diabetes mellitus (DM) and chronic kidney disease (CKD).The patients will be followed up every eight weeks.Fasting plasma glucose ,BUN creatinine and 24 hour urine protein were measured at each study visit.Patients were scheduled for follow-up visits at months 2,4,and 6.After 6 months ,all the blood tests,CAC score and CAVI will be done again.
Study: NCT01760343

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Berinert
Description: Berinert is a plasma-derived C1 esterase inhibitor (human), supplied as a freeze-dried powder for reconstitution.
Study: NCT01163409

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercise, Acupuncture and Fibromyalgia
Description: Set of real acupuncture treatment and supervised aerobic exercise have better efficacy in pediatric patients with fibromyalgia versus treatment with sham acupuncture and supervised aerobic exercise, as well as treatment versus combination with aerobic exercise and resistance exercise the major muscle groups, both supervised versus group control, we just get guidance for physical activity.

Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Exercise, Acupuncture and Fibromyalgia
Description: Set of real acupuncture treatment and supervised aerobic exercise have better efficacy in pediatric patients with fibromyalgia versus treatment with sham acupuncture and supervised aerobic exercise, as well as treatment versus combination with aerobic exercise and resistance exercise the major muscle groups, both supervised versus group control, we just get guidance for physical activity.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercise, Acupuncture and Fibromyalgia
Description: Set of real acupuncture treatment and supervised aerobic exercise have better efficacy in pediatric patients with fibromyalgia versus treatment with sham acupuncture and supervised aerobic exercise, as well as treatment versus combination with aerobic exercise and resistance exercise the major muscle groups, both supervised versus group control, we just get guidance for physical activity.
Study: NCT04090593

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Education 101: Mobile Health Education Tool
Description: Intervention is interactive, mobile (tablet-or-smart-phone delivered), educational module that patients engage with during hospital admission.
Study: NCT01760343

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Berinert
Description: Berinert is a plasma-derived C1 esterase inhibitor (human), supplied as a freeze-dried powder for reconstitution.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL830
Description: CSL830 is a formulation of Berinert.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL830
Description: CSL830 is a formulation of Berinert.
Study: NCT01270815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin controlled release, 330 mg, 400 to 500 calories
Description: A single oral dose of 330 mg controlled release tablet administered following a 400 to 500 calorie medium-fat lunch

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin controlled release, 330 mg, 600 to 750 calories
Description: A single oral dose of 330 mg controlled release tablet administered following a 600 to 750 calorie medium-fat lunch
Study: NCT01966367

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD34 Stem Cell Selection Therapy
Description: The CliniMACS (PLUS) Reagent System (Miltenyi CliniMACS CD34+ Cell Selection Device) will be used to remove T-cells from the peripheral blood stem cell transplant in order to decrease the risk of acute and chronic graft versus host disease (GVHD).
Study: NCT03237728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.06mg/kg,KB
Description: 0.06mg/kg,Q8h,Day1-Day7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.12mg/kg,KB
Description: 0.12mg/kg,Q8h,Day1-Day7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.24mg/,KB
Description: 0.24mg/kg,Q8h,Day1-Day7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: Placebos,Q8h,Day1-Day7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: Placebos,Q8h,Day1-Day7
Study: NCT02433236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib Disodium tablet 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib Disodium tablet 150 mg
Study: NCT01270815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin controlled release, 330 mg, 800 to 1000 calories
Description: A single oral dose of 330 mg controlled release tablet administered following an 800 to 1000 calorie medium-fat lunch

Intervention type: DRUG
Group type: OTHER
Intervention: Pregabalin immediate release, 300 mg
Description: A single oral dose of 300 mg immediate release capsule administered fasted
Study: NCT02465203

Intervention type: DRUG
Group type: OTHER
Intervention: Previous treatment in DEB025 study
Description: Follow-up after DEB025 active study
Study: NCT00042991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gefitinib
Description: Given orally
Study: NCT01832272

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reinflation after early tourniquet deflation
Description: The tourniquet is released after cement implant fixation, and then reinflated, once arterial bleeding was controlled
Study: NCT03125421

Intervention type: PROCEDURE
Group type: OTHER
Intervention: standard preventive methods of pressure sores
Description: During the control period, the following specific methods to prevent pressure sores in the prone position (in ARDS patients mechanically ventilated via tracheal route) will be these ongoing in each center and involve the following components: lower eyelid and ocular protection by any method, inclination of the body from the horizontal position, intermittent head mobilization to the right or to the left, and no use of specific device to prevent pressures sores at the head and/or thorax, and/or knees, and/or feet.~The following nonspecific methods to prevent pressures sores will be performed at the discretion of each center according to its usual practice: mattress, upper eyelid protection, main devices securely fasten, arms position, abdomen supported or not, mouth care, enteral nutrition continued in the prone position, skin protection and/or massage.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: experimental multifaceted preventive methods of pressure sores
Description: During the experimental period, the following specific methods to prevent pressure sores in the prone position (in ARDS patients mechanically ventilated via tracheal route) will be systematically applied: lower eyelid protection by horizontal strap, ocular protection by methylcellulose, 15° inclination of the body from the horizontal position, intermittent head mobilization to the right or to the left every four hours, and use of specific device to prevent pressures sores at the head, thorax, knees, and feet.~The following nonspecific methods to prevent pressures sores will be applied as in the control period described above except for the following: the abdomen will not be supported and the skin will not be protected.
Study: NCT02443727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Syntocinon (synthetic oxytocin)
Description: Dosage and details described in arm.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosage and details described in arm.
Study: NCT02314299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTP-131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTP-131
Study: NCT02206776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Ketamine
Description: A single dose of intranasal ketamine up to 50 mg
Study: NCT02990429

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Forced Air warmer
Description: * record room temperature~* record core temperature (tympanic membrane)~* General anesthesia~* using forced air warmer (bair hugger)~* Intravenous fluid at room temperature~* room temperature and core temperature q15 minutes~* anesthesia finish, stop bair hugger~* record core temperature before recovery room
Study: NCT02206776

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intranasal Midazolam
Description: A single dose of intranasal Midazolam up to 4 mg
Study: NCT02990429

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intravenous Fluid Warmer
Description: * record room temperature~* record core temperature (tympanic membrane)~* General anesthesia~* using ranger warmer~* Intravenous fluid at room temperature~* room temperature and core temperature q15 minutes~* anesthesia finish, stop ranger warmer~* record core temperature before recovery room
Study: NCT01356615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low molecular weight heparin (enoxaparin sodium)
Description: Enoxaparin sodium (Clexane; 40 mg) was administered 3-4 min before dialysis as a bolus dose, into the arterial line pre-dialyzer.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard unfractionated heparin
Description: Heparin (sodium heparin 5000 IU/ml) was administered as a bolus dose (50 IU/kg body weight) intravenously into the pre-dialyzer arterial line of the extracorporeal blood circuit, followed by a maintenance dose of 1000 IU sodium heparin per hour.
Study: NCT02061020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis (THC) in cigarettes of 30mg, 10mg and placebo
Description: Smoked THC containing cigarettes. Randomly allocated dosage 30mg, 10mg et placebo.~Both chronic and occasional cannabis consuming volunteers will be allocated to smoking a cigarette containing (1) no THC (placebo), (2) a joint containing 1% THC (10 mg THC, i.e. low-dose) and (3) a joint containing 3% (30 mg THC) mixed with 1 g tobacco.~Each cigarette will be followed by 24 hours testing in laboratory conditions. Each period is separated by 7 days (3 testing periods over 3 weeks). Each volunteer will undergo performance testing (driving simulator and PVT) before administration of the substance (T0).~Blood samples and repeat performance testing will be carried out at 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours and 24 hours.
Study: NCT04076930

Intervention type: DRUG
Intervention: angiotensin-converting enzyme inhibitor (ACEI) and angiotensin receptor blocker (ARB)
Description: The use of ACEI/ARB within a 90-day after the date of PD initiation (exposure ascertainment window period).
Study: NCT05688917

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Green coffee been extract
Description: supportive treatment
Study: NCT02061020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis (THC) in cigarettes of 30mg, 10mg and placebo
Description: Smoked THC containing cigarettes. Randomly allocated dosage 30mg, 10mg et placebo.~Both chronic and occasional cannabis consuming volunteers will be allocated to smoking a cigarette containing (1) no THC (placebo), (2) a joint containing 1% THC (10 mg THC, i.e. low-dose) and (3) a joint containing 3% (30 mg THC) mixed with 1 g tobacco.~Each cigarette will be followed by 24 hours testing in laboratory conditions. Each period is separated by 7 days (3 testing periods over 3 weeks). Each volunteer will undergo performance testing (driving simulator and PVT) before administration of the substance (T0).~Blood samples and repeat performance testing will be carried out at 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours and 24 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis (THC) in cigarettes of 30mg, 10mg and placebo
Description: Smoked THC containing cigarettes. Randomly allocated dosage 30mg, 10mg et placebo.~Both chronic and occasional cannabis consuming volunteers will be allocated to smoking a cigarette containing (1) no THC (placebo), (2) a joint containing 1% THC (10 mg THC, i.e. low-dose) and (3) a joint containing 3% (30 mg THC) mixed with 1 g tobacco.~Each cigarette will be followed by 24 hours testing in laboratory conditions. Each period is separated by 7 days (3 testing periods over 3 weeks). Each volunteer will undergo performance testing (driving simulator and PVT) before administration of the substance (T0).~Blood samples and repeat performance testing will be carried out at 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours and 24 hours.
Study: NCT00042991

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo standard brain irradiation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT03841500

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biocomposite intereference screw femoral tunnel fixation
Description: ACL reconstruction using biocomposite intereference screw for femoral tunnel fixation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endobutton (Tightrope) femoral tunnel fixation
Description: ACL reconstruction using endobutton (Tightrope) for femoral tunnel fixation
Study: NCT02094131

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Voldyne group (VG)
Description: VG: slow deep breaths through the mouthpiece of the incentive Voldyne5000® were conducted from the tidal volume (TV) until the total lung capacity (TLC), holding the maximum inspiration. All individuals should maintain yellow cup (yellow flow cup) at a range of flow Best in as long as possible. The training lasted approximately 50 minutes, were held twice a week on alternate days, for five consecutive weeks, totaling 10 sessions. Performed three sets of 15 repetitions.
Study: NCT05688917

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule
Study: NCT02287922

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALX-0061

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALX-0061

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALX-0061

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT02094131

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cliniflo group (CG)
Description: CG: slow deep breaths through the mouthpiece of the incentive Cliniflo® from tidal volume (TV) were performed until the total lung capacity (TLC), holding the maximum inspiration. The volume flow of 100 ml / s for Cliniflo® was standardized, being envisaged to keep the yellow indicator behind the happy face for all individuals.The training lasted approximately 50 minutes, were held twice a week on alternate days, for five consecutive weeks, totaling 10 sessions. Performed three sets of 15 repetitions.
Study: NCT04647006

Intervention type: PROCEDURE
Group type: OTHER
Intervention: thyroid
Description: Conventional Thyroidectomy and Transoral endoscopic thyroidectomy vestibular approach

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: thyroid
Description: Conventional Thyroidectomy and Transoral endoscopic thyroidectomy vestibular approach
Study: NCT04350749

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PRF is added in the test group.
Description: The PRF membrane can be considered as a biological membrane

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRF is added in the test group.
Description: The PRF membrane can be considered as a biological membrane
Study: NCT00042991

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01448499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clozapine
Description: escalating dose of clozapine up to 900 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amisulpride
Description: escalating dose of amisulpride up to 800 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clozapine+Amisulpride
Description: augmentation of clozapine with amisulpride